Conference Call Participants Operator And I would now like to hand the conference over to your speaker today, Ms. Stephanie Lee. Please go ahead. Roivant Sciences Ltd. (NASDAQ:ROIV) Q2 2023 Earnings Conference Call November 13, 2023 8:00 AM ET Stephanie Lee - Vice President, Special Projects Matt Gline - Chief Executive Officer Mayukh Sukhatme - President and Chief Investment Officer Frank Torti - Managing Director, Vant Chair David Risinger - Leerink Partners Brian Cheng - JPMorgan Yaron Werber - TD Cowen ...

November 13, 2023 Matthew Gline Chief Executive Officer Richard Pulik Chief Financial Officer Frank Torti, MD Vant Chair Eric Venker, MD, PharmD President and Chief Operating Officer Mayukh Sukhatme, MD President and Chief Investment Officer Forward-Looking Statements This presentation includes forward-looking statements that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. All statements other than st ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-40782 ROIVANT SCIENCES LTD. (Exact name of Registrant as specified in its Charter) Bermuda 98-1173944 (State or other jurisdiction of incorporation or organi ...

Yes. Thanks, Brian. And maybe IÂ'll take one second to that question and then also hand it over to Mayukh, to see if heÂ's got further comments. Look, I think in terms of the confidence in SLA, and I think you heard Mayukh said, on the one hand, I think thereÂ's a strong biological rationale that hitting both TYK2 and JAK1 should provide a meaningful benefit. Mayukh Sukhatme And maybe just one more follow-up on Immunovant 1402 data coming up next next month. Just to prep us for the top line coming up. Can y ...

| --- | --- | |-------|-------| | | | | | | August 14, 2023 Forward-Looking Statements Forward–Looking Statements This presentation includes forward-looking statements that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, busine ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-40782 ROIVANT SCIENCES LTD. (Exact name of Registrant as specified in its Charter) Bermuda 98-1173944 (State or other jurisdiction of incor poration or organizati ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40782 ROIVANT SCIENCES LTD. (Exact name of Registrant as specified in its Charter) Bermuda 98-1173944 (State or other juris diction of ...

$900 - $1,300 $1,300 - $1,500($1,325) Topical WAC Price Landscape Rationale for VTAMA Cream WAC Price o Reflects novel mechanism and differentiated profile with strongest on-label remittive effect for a topical Accelerates Launch Velocity & Enables Broad Adoption All trademarks are property of their respective owners. Based on RedBook drug pricing database, extracted May 2022. WAC prices based on 60g tubes, except for Duobrii, which is based on 100g tube. * WAC price for Atopic Dermatitis IGA Score 0 or 1 a ...

| --- | --- | |----------------------------------------|-------| | | | | Financial Results and Business Update | | February 13, 2023 Forward-Looking Statements Forward–Looking Statements This presentation includes forward-looking statements that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. All statements other than statements of historical facts contained in this presentation, including statements ...

Roivant Sciences Ltd. (NASDAQ:ROIV) Q3 2022 Earnings Conference Call February 13, 2023 8:00 AM ET Company Participants Stephanie Lee - Investor Relations Matthew Gline - CEO Frank Torti - MD, Vant Chair Mayukh Sukhatme - President & Chief Investment Officer Conference Call Participants Brian Cheng - JP Morgan Louise Chen - Cantor Neena Bitritto-Garg - Citi Robyn Karnauskas - Truist Corinne Jenkins - Goldman Sachs Dennis Ding - Jefferies Douglas Tsao - HCW Operator Good day, and thank you for standing by. We ...